Clinical and therapeutic profile of patients with glaucoma treated with latanoprost without macroglycerol-40 hydroxystearate (MGHS-40) - observational study

• Authors: Małgorzata Zdzieszyńska

Abstracts

EN

Purpose: The aim of the study was to evaluate the clinical and therapeutic profile of patients with open-angle glaucoma (OAG) and intraocular hypertension (IHT) who were treated with latanoprost eye drops without macroglycerol-40 hydroxystearate (MGHS-40).
Methods: This was a multicenter, open-label, observational, non-interventional study evaluating the clinical and therapeutic profile of patients with glaucoma who received therapy with latanoprost eye drops, without MGHS-40. The study, conducted between April 2022 and July 2023, involved 7171 patients and 270 physician-investigators from across the country. The study included adult patients with OAG and IHT in whom the physician made an independent decision to change therapy or include a drug containing latanoprost without MGHS-40.
Results: The results of the study showed that the mean intraocular pressure in this group of patients was 22.6 mmHg. Most of the study participants had a diagnosis of comorbidities – the most common being high blood pressure. Risk factors for OAG were also noted in more than 70% of patients. Predominant among these were a positive family history and smoking.
Conclusion: Our study shows that the latanoprost therapy without MGHS-40 is effective in lowering intraocular pressure. The main factors determining a doctor’s decision to use latanoprost without MGHS-40 were good topical tolerability and a simple formulation. The results suggest that this formulation has properties that could enhance patient compliance, possiblyincreasing long-term intraocular pressure-lowering effectiveness.

Keywords

EN

glaucoma; treating with latanoprost; latanoprost without macroglycerol-40 hydroxystearate; MGHS-40

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2024
• Volume: 11
• Issue: 2
• Pages: 137-145

Dates

published

2024

Contributors

author

Małgorzata Zdzieszyńska

• Ophthalmology Centre, Individual Specialized Medical Practice, Łódź

References

• Kluk A, Sznitowska M, Substancje pomocnicze w lekach do oczu. Farm Pol. 2010; 66(8): 567-72.
• Misiuk-Hojło M, Mulak M. Leki bez konserwantów - czy już standard w terapii jaskry? Przegl Okul. 2018; 15(4): 1-2.
• Polskie Towarzystwo Okulistyczne 2022. Wytyczne diagnostyki i leczenia jaskry (aktualizacja 2022).
• Smedowski A, Paterno JJ, Toropainen E. Excipients of preservative-free latanoprost induced inaflmmatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. J Biochem Pharmacol Res. 2014; 2(4): 175-84.
• Janicki S, Fiebig A, Sznitowska M. Farmacja Stosowana. Podręcznik dla Studentów Farmacji. Wydanie IV uzupełnione. Warszawa 2013.
• Bacharach J, Ahmed IIK, Sharpe ED et al. Preservative-Free versus Benzalkonium Chloride-Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clin Ophthalmol. 2023; 17: 2575-88. http://doi.org/10.2147/OPTH.S414015.
• Davuluru SS, Jess AT, Kim JSB et al. Identifying, understanding, and addressing disparities in glaucoma care in the United States. Transl Vis Sci Technol. 2023; 12(10): 18. http://doi.org/10.1167/tvst.12.10.18.
• Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11): 2081-90. http://doi.org/10.1016/j.ophtha.2014.05.013.
• Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020; 12(11): e11686. http://doi.org/10.7759/cureus.11686.
• Osial N, Kaczyńska A, Gorecka A et al. Glaucoma - the signicfiant challenge for the healthcare system in Poland. Journal of Education, Health and Sport. 2022; 12(7): 30-39. http://doi.org/10.12775/jehs.2022.12.07.004.
• European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th ed. Br J Ophthalmol. 2021; 105(Suppl 1): 1-169.
• Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014; 8: 1967-85. http://doi.org/10.2147/OPTH.S59162.
• Jóhannesson G, Stille U, Taube AB et al. Guidelines for the management of open-angle glaucoma: National Program Area Eye Diseases, National Working Group Glaucoma. Acta Ophthalmol. 2024; 102(2): 135-50. http://doi.org/10.1111/aos.16599.
• Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997; 41(Suppl. 2): S105-10.
• Harasymowycz P, Hutnik C, Rouland JF et al. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis. Adv Ther. 2021; 38(6): 3019-31. http://doi.org/10.1007/s12325-021-01731-9.
• Lee JW, Ahn HS, Chang J, Kang HY et al. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. Korean J Ophthalmol. 2022; 36(5): 423-34. http://doi.org/10.3341/ kjo.2022.0061.
• Reisner P, Malukiewicz G. Diagnostics, classicfiation and treatment of dry eye syndrome in the era of COVID-19. Klinika Oczna / Acta Ophthalmologica Polonica. 2021; 123(1): 8-13. doi:10.5114/ko.2021.104746.
• Nijm LM, Schweitzer J, Gould Blackmore J. Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat. Clin Ophthalmol. 2023; 17: 3063-76. http://doi.org/10.2147/OPTH.S420932.
• Chen HY, Lin CL, Tsai YY et al. Association between glaucoma medication usage and dry eye in Taiwan. Optom Vis Sci. 2015; 92(9): e227- 32. http://doi.org/10.1097/OPX.0000000000000667.
• Baudouin C, Renard JP, Nordmann JP et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013; 23(1): 47-54. http://doi.org/10.5301/ejo.5000181.
• Gasser P, Flammer J. Blood-cell velocity in the nailfold capillaries of patients with normal-tension and high-tension glaucoma. Am J Ophthalmol. 1991; 111: 585-8. http://doi.org/10.1016/S0002-9394(14)73703-1.
• Gasser P, Flammer J, Guthauser U et al. Do vasospasms provoke ocular diseases? Angiology. 1990; 41: 213-20. http://doi.org/ 10.1177/000331979004100306.
• Gasser P. Ocular vasospasm: a risk factor in the pathogenesis of low-tension glaucoma. Int Ophthalmol. 1989; 13: 281-90. http://doi.org/ 10.1007/BF02280088.
• Huang JY, Su CC, Wang TH et al. Migraine and increased risk of developing open angle glaucoma: a population-based cohort study. BMC Ophthalmol. 2019; 19: 50. https://doi.org/10.1186/s12886-019-1062-9.
• Epstein SP, Ahdoot M, Marcus E et al. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009; 25(2): 113-9.

Identifiers

DOI

10.24292/01.OT.200624

Biblioteka Nauki

61650568